[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2012DN01493A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01493A
IN2012DN01493A IN1493DEN2012A IN2012DN01493A IN 2012DN01493 A IN2012DN01493 A IN 2012DN01493A IN 1493DEN2012 A IN1493DEN2012 A IN 1493DEN2012A IN 2012DN01493 A IN2012DN01493 A IN 2012DN01493A
Authority
IN
India
Prior art keywords
alcoholic
melancortin
dyslipidemia
receptor
useful
Prior art date
Application number
Inventor
Heather A Halem
Michael Dewitt Culler
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of IN2012DN01493A publication Critical patent/IN2012DN01493A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease.
IN1493DEN2012 2009-08-05 2010-07-30 IN2012DN01493A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27348809P 2009-08-05 2009-08-05
PCT/US2010/043832 WO2011017209A1 (en) 2009-08-05 2010-07-30 Use of melanocortins to treat dyslipidemia

Publications (1)

Publication Number Publication Date
IN2012DN01493A true IN2012DN01493A (en) 2015-06-05

Family

ID=43544604

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1493DEN2012 IN2012DN01493A (en) 2009-08-05 2010-07-30

Country Status (12)

Country Link
US (2) US20120135923A1 (en)
EP (1) EP2461681A4 (en)
JP (1) JP2013501053A (en)
KR (1) KR20120059520A (en)
CN (1) CN102548399A (en)
AU (1) AU2010279719A1 (en)
BR (1) BR112012002445A2 (en)
CA (1) CA2769883A1 (en)
IN (1) IN2012DN01493A (en)
MX (1) MX2012001513A (en)
RU (1) RU2012108110A (en)
WO (1) WO2011017209A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555522T3 (en) 2007-11-05 2016-01-04 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
EP2501712A4 (en) * 2009-11-16 2013-09-04 Ipsen Pharma Sas Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2
ES2718655T3 (en) * 2011-06-14 2019-07-03 Ipsen Pharma Sas Sustained release composition containing peptides as active ingredient
EP2797615B1 (en) 2011-12-29 2019-04-03 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2725150C2 (en) 2013-03-15 2020-06-30 Ритм Фармасьютикалз, Инк. Peptide compositions
DK2970389T3 (en) 2013-03-15 2020-10-26 Rhythm Pharmaceuticals Inc Pharmaceutical compounds
WO2017059076A1 (en) 2015-09-30 2017-04-06 Rhythm Pharmacueticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders
US20210221867A1 (en) * 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc Combination therapy for the treatment of dyslipidemia
JP2008519008A (en) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ Peptides for use in the treatment of obesity
RU2401841C2 (en) * 2005-07-08 2010-10-20 Ипсен Фарма С.А.С. Ligands of melanocortin receptors
ES2604328T3 (en) * 2005-07-08 2017-03-06 Ipsen Pharma Melanocortin receptor ligands
RU2450017C2 (en) * 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Hydantoin modified melanocortin receptor ligands
US20100173834A1 (en) * 2007-06-15 2010-07-08 Zheng Xin Dong Cyclic peptide melanocortin receptor ligands
ES2555522T3 (en) * 2007-11-05 2016-01-04 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity

Also Published As

Publication number Publication date
CA2769883A1 (en) 2011-02-10
WO2011017209A1 (en) 2011-02-10
CN102548399A (en) 2012-07-04
MX2012001513A (en) 2012-05-22
AU2010279719A1 (en) 2012-03-01
RU2012108110A (en) 2013-09-10
EP2461681A4 (en) 2013-04-24
EP2461681A1 (en) 2012-06-13
JP2013501053A (en) 2013-01-10
US20130331324A1 (en) 2013-12-12
KR20120059520A (en) 2012-06-08
BR112012002445A2 (en) 2015-10-13
US20120135923A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
IN2012DN01493A (en)
AP2011005777A0 (en) Methods and compositions related to thioesterase enzymes.
JO3118B1 (en) Compositions and methods for antibodies targeting complement protein c5
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
EA201200091A1 (en) STRAINS TALAROMYCES AND ENZYME COMPOSITIONS
NZ595939A (en) Use of modified peptide gamma-glu-abu for imparting or enhancing food or beverage taste
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
WO2009049284A3 (en) Compositions and methods for improved glycoprotein sialylation
WO2012058588A3 (en) Novel egfr-binding molecules and immunoconjugates thereof
MY159398A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
IL212066A (en) Anti cxcr4 antibodies, compositions comprising them, processes for their production and selection and use thereof
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012005037A (en) Dual variable domain immunoglobulins and uses thereof.
MX2012004415A (en) Dual variable domain immunoglobulins and uses thereof.
MX2012001262A (en) Dual variable domain immunoglobulins and uses thereof.
MX2011011669A (en) Dual variable domain immunoglobulins and uses thereof.
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
MX2010007867A (en) Concentrated personal cleansing compositions.
MX2010003013A (en) Inhibition of angiogenesis.
WO2010151541A8 (en) Polymorphic form d of bazedoxifene acetate and methods of preparing same
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
MX2012001306A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists.
EA201101214A1 (en) POLYENE COMBINATION COMPOSITIONS
HK1162058A1 (en) Tanning process and tanning composition